bronchial asthma pharmacology and clinical aspects
TRANSCRIPT
BRONCHIBRONCHIAAL ASTL ASTHHMA MA PhPharmaarmaccololooggyy a andnd
CCliniclinicalal AAspespeccttss
DEFINDEFINITION ABITION AB
Asthma bronchiale is chronic inflammatory disease of airways connected with bronchial hyperreactivity and totally or partially reversible obstruction of airways, which in the most cases dissapears spontaneously or with treatment.
ASTHMA BRONCHIALEASTHMA BRONCHIALE• reversible obstruction• daily symptom variability• family history• beginning at any age, most often
– 10-15% children– 5-10% adults
• no smoking• allergy, rhinitis, eczema - may / may not
GINAGINA1995, 2002, 20061995, 2002, 2006
Celosvetová iniciatíva pre astmu
ETIOPATOGENESISETIOPATOGENESIS• INFLAMMATIONINFLAMMATION activation of mastocytes,
macrophages, eosinophils, helper Th-lymfocytes => formed and released inflammatory mediators: histamine, leucotriens, prostaglandins, bradykinin
bronchoconstriction, mucus secretion, plasma exudation and bronchial hyperreactivity, airway remodelation
insufficient anti-inflammatory therapy => progressive destructive changes fixing of airway obstruction to emphysematous changes
Triggers of Symptoms and Exacerbations Triggers of Symptoms and Exacerbations
• allergens• factors of air pollution (including cigarette smoke)• respiratory infections, particularly viral (RSV,
rhinoviruses, influenza viruses, chlamydia)• physical activity and hyperventilation (by osmotic
processes)• wheather changes• food and drugs (ASA, NSAID, -blockers)• emotional stress• gastroesophageal reflux
CLINICAL SYMPTOMS OF ABCLINICAL SYMPTOMS OF AB
• Emphasis on early diagnosis Emphasis on early diagnosis management begins with right analysis of
symptoms
- to them belong:• dyspnoe• cough• chest tightness• wheezing
CClasification of Asthma according to clinical symptoms and lung lasification of Asthma according to clinical symptoms and lung function:function:
DEGREE OF SERIOUSNESS
SYMPTOMS DURING DAY SYMPTOMS DURING NIGHT
LUNG FUNCTION
IV. severe persistent A
sy. continuously, attacks often, physical activity limited Often
PEF 60%Nvariability of PEF 30%
III. moderate persistent
sy. daily, attacks 2/week, influencing activity 1/week
PEF = 60-80%Nvariability of PEF 30%
II. mild persistent A
sy. 2/week daily, attacks 2/week, changing activity
2/month
PEF 80%Nvariability of PEF =20-30%
I. mild intermittent A
sy. 2/week, only mild or no attacks, aktivity unchanged
2/monthPEF 80%Nvariability of PEF 30%
GINA
2002
Levels of Asthma Control GINA 2011
Assessment of current clinical control (preferably over 4 weeks)Characteristics Controlled (all
of the following)Partly Controlled (any measure presented)
Uncontrolled
Daytime symptoms None (twice or less / week)
More than twice / week Three or more features of partly controlled asthmaLimitations of activities None Áno
Nocturnal symptoms / awaking
None Áno
Need for reliever / rescue inhaler
None (twice or less / week)
More than twice / week
Lung function / (PEF or FEV1)
Normal < 80 % predicted or personal best (if known)
Assessment of future risk (risk of exacerbation, instability, rapid decline in lung function, side effects)Poor clinical control, frequent exacerbations in past year, ever admission to critical care for asthma, low FEV1, exposure to cigarette smoke, high dose medications
GINA
2006
CLINICAL SIGNS OF ABCLINICAL SIGNS OF AB• depends on the stage of asthma• intermittent attacks of expiration type dyspnoe, ich
worsening at night and at dawn• wheezing: intermittent, more significant at expiration• cough: usually not productive, can be basic sign• anxiety, pressure, chest tightness, dyspnoe• sputum production usually little, if than väzký mucus• prodromal signs prior attack: itching under the chin,
discomfort between shoulder blades, fear, anxiety• typical is vanishing of signs after b-dilatances or
antiinflammatory therapy, unsuccessful ATB th.
DIAGNOSISDIAGNOSIS• PRINCIPLE: simple examinations made
repeatedly are more usefull than complete examinations made at one time or during long intervals limitation of expiratory flow at asthma has variable character findings may vary from completely normal to absolutely pathological
• Functional diagnostics• Allergologic diagnostics• Specifying of inflammation markers
EXAMINATIONS AT ABEXAMINATIONS AT AB• SPIROMETRY • BRONCHODILATION TESTS (BDT)
– it verifies the degree of obstruction reversibility• BRONCHOPROVOKING TEST (BKT)
– BKT with histamine, ACh, adenosine, excercise, cold... – negativenegative BKT excludes dg. of ABexcludes dg. of AB (absence of bronchial
hyperreactivity...)• PEF variability by výdychomerom (self monitoring)• ARTERIAL BLOOD GASES (at exacerbation)• Determination of NO in exhaled air (early marker of asthmatic
inflammation)
• SPUTUM EXAMINATION – eosinophils and their effective products, Curshmann´s
spirals, Charcot-Leyden´s crystalls
SPIROMETRYSPIROMETRY• simple, reproductible• gives informations about
restriction of air flow• – FVC (forced vital
capacity) – FEV1 (sec. vital cap.) – FEV3 (forced expiratory
flow at 50% expiration) – FEV1/VC – Tiffaneau´s
index (FEV3/VC)– PEF (peak expiratory
flow in l/min)
DIFERENTIAL DIAGNOSISDIFERENTIAL DIAGNOSIS• chronic obstructive pulmonary disease• asthma cardiale at older adults• viral bronchiolitis at children• hyperventilatory syndrom• fixed obstacles in the airways (tumors,
extramural compression, foreign particles)• diffuse interstitial lung processes• pneumothorax• chest wall diseases (kyphoscoliosis,
neuromuscular diseases)
Beginning in middle age Beginning in younger age
Symptoms progress slowlyprogress slowly Symptoms from day to day changing
Long anamnesis of smoking Symptoms in the afternoon or early morning
Dyspnoe at excercise Also allergy, rhinitis, eczema
Larger irreversible restriction of air flow
Usually reversible restriction of air flow bmedzenie
Family history of asthma
CHOPDCHOPDCHOPDCHOPD Asthma BronchialeAsthma BronchialeAsthma BronchialeAsthma Bronchiale
PulmonaryPulmonaryfunctionsfunctions
SymptomsSymptoms
CH O P DCH O P DCH O P DCH O P D
SymptomsSymptoms PulmonaryPulmonaryfunctionsfunctions
A S T H M AA S T H M AA S T H M AA S T H M A
GOALS of Optimal AB ControlGOALS of Optimal AB Control- elimination or significant reduction of reduction of symptomssymptoms- prevention of exacerbationsprevention of exacerbations- maintaining lung functionslung functions closest to
physiological values - maintaining normal physical and living activity - absence of treatment adverse effects - prevention of irreversibleirreversible bronchial obstruction
(remodelation of lower airways)- preventing asthma mortalitypreventing asthma mortality
THERAPY OF ABTHERAPY OF AB
• NonpharmacologicalNonpharmacological– Patients´ education – avoiding risk factors and triggers-
• PharmacologicalPharmacological– A N T I I N F L A M M A T O R Y
• relieves inflammation and bronchial hyperreactivity• regular, long-term use
– B R O N CH O D I L A T O R Y• eliminates the symptoms of expiratory flow limitation • rescue therapy in exacerbation
Administration of Drugs at AB
peroral parenteralby inhalation directly to the site of action fast beginning of actionmaximum efficacy lower therapeutic doses = minimalise risk of AE limitationslimitations from the site of patient from the site of patient (technique of
inhalation, cooperation...) inspiratory resistanceinspiratory resistance, needs to be overcomed
Administration of Drugs at AB
peroral parenteralby inhalation directly to the site of action fast beginning of actionmaximum efficacy lower therapeutic doses = minimalise risk of AE limitationslimitations from the site of patient from the site of patient (technique of
inhalation, cooperation...) inspiratory resistanceinspiratory resistance, needs to be overcomed
Inhalatory Systems
Nowadays
THERAPY OF ABTHERAPY OF ABA: A: CONTROLLERSCONTROLLERS
– preventive drugs, controlling inflammationcontrolling inflammation – are taken regularly,long timeregularly,long time to maintain control
antiinflammatory drugsantiinflammatory drugs long acting inhalatory bronchodilators long acting inhalatory bronchodilators B: B: RELIEVERSRELIEVERS substances releasing bronchospasm relieving = fast acting bronchodilatorsC: OTHER ANTIASTHMATIC DRUGSC: OTHER ANTIASTHMATIC DRUGS
– Monoclonal Ab against IgE = omalizumab (50 pat. in SR)– ketotifen – Imunosupressives (MTX, CysA...)
A: A: CONTROLLERSCONTROLLERS
• inhalatory corticoids ICS
• long-acting 2-sympathomimetics
(long-acting betaagonists ) LABA, (8-15h.)
• antileukotriens LTRAs– leukotriene receptor antagonists
– inhibitors of 5-lipooxygenase (zileuton)
• retard methylxanthines
• cromones
B: RELIEVERS
• inhalatory short-acting 2-sympathomimetics
(short-acting betaagonists ) SABA (till 4-6 h.)
• inhalatory anticholinergics short-acting
• systemic corticoids p.o./i.v. („rescue“ treatment)
• some sources – controllers
• fast acting methylxantines
INHALATORY CORTICOIDS INHALATORY CORTICOIDS ICSICS
the most effective antiinflammatory antiasthmatics • to long-term use at all forms of AB
• Mechanism of action:1. inhibition of cytokine transcription antiinflam. ef. 2. inhibition of mediators of inflam. release3. decrease of airways reactivity 4. restriction of vasodilation antioedematic ef.5. affect synthesis of eikosanoids 6. control activation of adhesive molecules 7. increase of susceptibilityincrease of susceptibility resp. protection of 2 receptors against down-regulation at long-term treatment with 2 mimetics
ICSICS• AE locally can reduce with the use of attachments and
rinsing the mouth with NaHCO3
– oropharyngeal candidosis – dysphonia – seldomly irritation to cough
• risk of systemicsystemic AE is , depends on dose ,efficacy and pharmacokinetic of steroid
• inflammationinflammation in airways, bronchibronchialal hyperreahyperreacctivittivityy and obobsstrutruction ction of airways
• risk of AEAE (acute exacerbations) and control symptsymptoommss of disease
ICSICS
• beclomethasone • budesonide • fluticasone • ciclesonide – 1 times per day, minimal syst. AE,
prodrugprodrug-activation dirrectly in lungs, the part resorbed is inactive => systemic ef. !!!!!!
• mometasone
Principles of Treatment with Principles of Treatment with ICSICS 1. ICS need to be administered at each new dg. AB 2. Treatment is essential to start early
3. We administer attack doses of ICS 4. Reduction of dose only after longer stabilisation
(6 months) – than minimal effective dose 5. If not sufficient ICS, we add as the drug of the first choice LABA,
alternatives are leucotriene modifiers ( the first choice add-on therapy for children younger than 5 years), methylxanthines, slow release β2-agonists tablets
6. To adult patients are administered max. 200-800 mcg BDP/day and to children max. 400 mcg BDP/day, than you should start on with add-on therapy
ICS ICS in the Treatment ofin the Treatment of ABAB – – „stable „stable disease“disease“
according to British guidelines
• mild intermittent asthmamild intermittent asthma• inhaled short-acting β2-agonists as needed
• mildmild per perssististentent ast asthhmama monotmonothheraperapy with small doses ofy with small doses of ICSICS ( 500µg BDP/d)– addition of LABALABA will not reduce the symptoms unless they are
deteriorated resp. pulmonary functions are decreased
*BDP = Beclomethasone dipropionate CFC
ICS ICS in the Treatment ofin the Treatment of ABAB – – „stable disease“„stable disease“
• moderatemoderate per perssististentent ast asthhmama• inhalated short-acting β2-agonists regularly• if lack of control by ICS → add LABA:
1. good response to LABA → continue combination therapy LABA + ICS2. LABA effective, but inadequate control → increase the dose of ICS to
BDP 800 mcg/day3. LABA ineffective → quit LABA, increase the dose of ICS to
BDP 800 mcg/day → if still inadequate control → add other anti-asthmatics (leucotriene modifiers, methylxanthines)
• persistent poor controlpersistent poor control• inhalaled short-acting β2-agonists regularly• increase the dose of ICS• adding a fourth drug
ICS ICS in the Treatment ofin the Treatment of AB AB – – „exacerbations“„exacerbations“
• the bestthe best to addadd high dose ofhigh dose of ICS ICS toto regular maintenance therapy ICS+LABAICS+LABA
• at severesevere AE AE systsystemicemic CCSS
Adverse effects of systemically administered corticosteroids
• Infections• The long-term use may increase blood pressure, cause fluid retention and salt
retention in the body (oedema), increased excretion of calcium and potassium• Worse and longer wound healing• Rash and acne• Hyperglycaemia• They increase the risk of gastrointestinal perforation• Increased appetite and weight gain• Osteoporosis (↓ absorption of calcium, ↑ its excretion)• Muscle pain, muscle weakness and muscle cramps (especially ↑ loss of potassium,
↓ calcium level in the blood)• Cataract, increased intraocular pressure, optic nerve damage, eye infections• CNS: irritability, mood and personality changes, depression, headaches, dizziness
Management control of asthma GINA 2011 (adults and children older than 5 years)
STEP 1 STEP 2 STEP 3 STEP 4 STEP 5
Asthma education. Enviromental control.As needed SABA As needed SABA
CONTROLLER options
Select one Select one Select one or more Add eitherLow-dose ICS Low-dose ICS +
LABAMedium-dose or high-dose ICS + LABA
Oral glucocorticosteroid (lowest dose)
Leukotriene modifier
Medium-dose or high-dose ICS
Leukotriene modifier Anti – IgE treatment
Low-dose ICS + leukotriene modifier
Sustained release theophylline
Low-dose ICS + sustained release theophylline
ßß22- SYMPAT- SYMPATHHOMIMETIOMIMETICSCS
• Mechanism of action = agonistic, activating influence on ß2 receptors of sympathic NS
1. 1. Long-actingLong-acting ßß22SMSM (long-acting betaagonists ) = LABA
– Controllers – to long-term,regular bronchodilation
2. 2. Short-actingShort-acting ßß22SMSM (short-acting betaagonists ) = SABA
– Relievers – to short-term, acute management of exacerbation
ββ22 –sympathomimetics –sympathomimetics(LABA and SABA)(LABA and SABA)
Fast beginning,short duration
inhal. salbutamol, fenoterol
Fast beginning, long duration
inhal. formoterol
Slow beginning,short duration
oral salbutamol rtd. cps.
Slow beginning,long durationinhal. salmeterol
speed of effect beginning
FAST
SLOW
SHORT LONGduration of action
rescue treatment
mai
nta
nan
ce t
her
apy
LABASABA
ß2- sympatho MIMETICS = SM
Anti M -cholinergic = PsL
activate sympathic NS
dilate bronchi
block parasympathic NS
dilate bronchi
LoLoccalialisation ofsation of RReceptoreceptorss
cholinergcholinergicic (parasympat(parasympathhic)ic)
aadrenergdrenergicic
(sympat(sympathhic)ic)
LABALABA the best, fast and intense acting b-dilatans
duration ofduration of action action >>12 hours12 hours
MMAA:: Bronchodilation through β2 => relaxation of smooth muscle
Improve mucociliar clearens Lower vascular permeability Modulate release of mediators from mastocytes a bazophils Provide long-term safety against bronchoconstriction Length of this bronchodilation effect at long-term regular
administration decreases sign of tollerance for down regulation of β2 receptors => inhibition = concomitant administration of ICSLABA in long-term therapy of asthma never can administer lonely,
without ICS!
MoleMoleccululaar mechanir mechanissmm of of positive positive interainteractionction ICS a ICS andnd LABA LABA
Glucocorticoid receptor
ß2-Adrenoceptor
Corticosteroid
Anti-inflammatory effect
• Effect of corticosteroids on ßEffect of corticosteroids on ß22-adrenoceptors -adrenoceptors • Effect of ßEffect of ß22-agonists on glucocorticoid receptors-agonists on glucocorticoid receptors
ß2-Agonist
Bronchodilatation
LABA: zlepšenie utilizácie KS a internalizácie GR do jadra (translokácia GR)ICS: prevencia desenzitizácie a znižovania expresie β2 receptora
LABA• formoterol • salmeterol
MonotMonothheraperapyy LABA: LABA:• effectivity of LABA vs. ICS• improving sleeping, but withoutwithout ef efffeect toct to p pulmonaryulmonary
funfunctionsctions • discontinuationdiscontinuation ICS ICS and addingadding LABA LABA at persistent
asthma loosingloosing ccontrolontrol• good controlled patient with asthma with persistent
asthma at low dose ICS replacement byreplacement by LABA LABA loosingloosing ccontrolontrol ( eNo and Eo in sputum)
• withoutwithout e efffefect on inflam.ct on inflam. in airways (biopsia)
FDA – LABA drug safety communication 2011
• In February 2010, the agency announced it was requiring manufacturers to revise their drug labels because of an increased risk of severe exacerbation of asthma symptoms, leading to hospitalizations, in pediatric and adult patients, as well as death in some patients using LABAs for the treatment of asthma.
FDA – LABA drug safety communication 2011
• The new recommendations in the updated labels state:
• Use of a LABA alone without use of a long-term asthma control medication, such as an inhaled corticosteroid, is contraindicated (absolutely advised against) in the treatment of asthma.
• LABAs should not be used in patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids.
• LABAs should only be used as additional therapy for patients with asthma who are currently taking but are not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid.
• Once asthma control is achieved and maintained, patients should be assessed at regular intervals and step down therapy should begin (e.g., discontinue LABA), if possible without loss of asthma control, and the patient should continue to be treated with a long-term asthma control medication, such as an inhaled corticosteroid.
• Pediatric and adolescent patients who require the addition of a LABA to an inhaled corticosteroid should use a combination product containing both an inhaled corticosteroid and a LABA, to ensure adherence with both medications.
ANTILEUKOTRIENE DRUGSANTILEUKOTRIENE DRUGS
• controllers,controllers, for long-term control of symptoms • antagonists of leukotriene 1 (CysLT1) receptors
– montelukast, zafirlukast, pranlukast• inhibitors of 5-lipooxygenase
– zileuton • taken perorally • MA: - additive antiinflam. effect to ICS
- reduce tissue eosinophilia - mild bronchodilation ef. - bronchoprotective ef.
ANTILEUKOTRIENE DRUGSANTILEUKOTRIENE DRUGS
• role in therapy of AB - still unclear• are less effective than low doses of ICS• as additive drugs (in combination with ICS) reduce the need of steroid dose at
severe asthma
• again less effective than standard ICS+LABA• advantageous – aspirin asthma, by excercise induced asthma, „preschool
wheezing“ • compliance at taking tablet form
METHYLXANTHINESMETHYLXANTHINES• controllers, to long-lasting control of symptoms• Improvement of clinical symptomatology
– bronchodilation - without signif. increase of FEV1/ improvement of lung function parameters through inhibition of fosfodiesterase I. to IV. => cAMP
– antiinflam., immunomodulatory effects– positive effect on phenomenon of „corticoid resist.“
• AE: cephalea, nausea, vomiting, tachycardia, palpitations, plasm. conc. (TDM) arrhytmias, epileptic spasms even death
• potential toxicity, profile of AE bronchodilators of the third choice
METHYLXANTHINESMETHYLXANTHINES
Proven benefit bring only drug formsdrug forms providing long-lasting action with controlled releasewith controlled release
–with controlled release - p.o. • aminophylline, theophylline for using
during day time always + ICS – less effective than ICS+LABA
– with short-lasting ef. - p.o., i.v.with short-lasting ef. - p.o., i.v. • aminophylline
SABASABA
basic relieversbasic relievers used ad hoc to relieve or to remove symptoms no reason for regular administration
• salbutamol (Ventolin)• fenoterol /Australia – deregistered for AE CVS/
INHALATORY ANTICHOLINERGIC DRUGSINHALATORY ANTICHOLINERGIC DRUGS
Relievers of the second choice, at AERelievers of the second choice, at AE
competitivecompetitive antagonists antagonists on M1, M2 and M3 on M1, M2 and M3 receptors of parasympathicus
cholinergic tonuscholinergic tonus
Division:Division:
• with short-lastingshort-lasting effect: ipratropium bromideipratropium bromide• with long-lastinglong-lasting effect: tiotropium bromide (CHOPD)tiotropium bromide (CHOPD)
Pre-gangliovýnerv
Parasympatickéganglion
Post-gangliovýnerv
ACh
Hladký sval
Nicotinový receptor (+)
M1 receptor (+)
M2 receptor (–)
M3 receptor (+)
MusMusccarariinnicic receptory receptorys in s in airwaysairways
Barnes PJ. Eur Respir Rev 1996
INHALATORY ANTICHOLINERGIC DRUGSINHALATORY ANTICHOLINERGIC DRUGS
• decrease n. vagus tonus • cause relaxation• but no bronchoprotective action • are in general less effective than β2– mimethics
and have a little slower beginning of action • advantageous combinations v 1 inhalation
system:• ipratropium• ipratropium+fenoterol
Is this patient with asthma?
1st May, 2012